Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Catalent stock

CTLT
US1488061029
A112H2

Price

63.48
Today +/-
+0
Today %
+0 %

Catalent stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Catalent stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Catalent stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Catalent stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Catalent's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Catalent Stock Price History

DateCatalent Price
12/17/202463.48 undefined
12/16/202463.48 undefined

Catalent Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Catalent, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Catalent from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Catalent’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Catalent. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Catalent’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Catalent’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Catalent’s growth potential.

Catalent Revenue, EBIT and net profit per share

DateCatalent RevenueCatalent EBITCatalent Net Income
2030e6.83 B undefined0 undefined877.56 M undefined
2029e6.29 B undefined0 undefined710.94 M undefined
2028e5.82 B undefined1.2 B undefined564.68 M undefined
2027e5.59 B undefined735.93 M undefined442.49 M undefined
2026e5.15 B undefined538.69 M undefined279.33 M undefined
2025e4.76 B undefined447.62 M undefined204.45 M undefined
20244.38 B undefined-11 M undefined-1.04 B undefined
20234.26 B undefined113 M undefined-256 M undefined
20224.8 B undefined729 M undefined483 M undefined
20214 B undefined646 M undefined529 M undefined
20203.09 B undefined405.4 M undefined173 M undefined
20192.52 B undefined293.1 M undefined137.4 M undefined
20182.46 B undefined290 M undefined83.6 M undefined
20172.08 B undefined252 M undefined109.8 M undefined
20161.85 B undefined229.5 M undefined111.5 M undefined
20151.83 B undefined278 M undefined212.2 M undefined
20141.83 B undefined263.8 M undefined16.2 M undefined
20131.8 B undefined228 M undefined-49.6 M undefined
20121.69 B undefined210.5 M undefined-24.4 M undefined
20111.53 B undefined213.8 M undefined-54 M undefined
20101.48 B undefined170.8 M undefined-289.6 M undefined
20091.4 B undefined139.3 M undefined-308.1 M undefined

Catalent Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
1.41.481.531.691.81.831.831.852.082.462.523.0944.84.264.384.765.155.595.826.296.83
-5.873.4510.656.261.500.160.9812.2818.702.2322.8829.2220.11-11.222.778.678.078.594.138.138.49
27.1829.7332.7932.9431.5632.7333.6131.7631.5230.5331.9731.7733.8233.6124.4021.7520.0218.5217.0616.3815.1513.96
0.380.440.50.560.570.60.620.590.650.750.810.981.351.611.040.95000000
-308-289-54-24-491621211110983137173529483-256-1,043204279442564710877
--6.17-81.31-55.56104.17-132.651,225.00-47.64-1.80-23.8565.0626.28205.78-8.70-153.00307.42-119.5636.7658.4227.6025.8923.52
117.3117.3117.375.47576.1121.3125.9126.7133.2146152.3170178181181000000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Catalent Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Catalent is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2012201320142015201620172018201920202021202220232024
                         
13910674151132307410345953967538280289
0.340.360.40.370.420.490.560.720.91.191.451.41.51
0000000000000
130137147144166197220265347593724801603
977862707868546994165205210199
0.70.680.690.740.791.061.241.42.292.922.922.692.6
0.810.820.870.890.9111.271.5422.613.223.743.72
0000000000000
0000000000000
0.420.370.360.370.290.270.550.930.890.821.060.980.84
1.031.021.11.0611.041.42.222.472.523.013.042.33
1776075851058178100122250305325262
2.442.272.42.42.32.393.294.795.486.197.598.097.16
3.142.953.093.143.093.464.536.187.789.1110.5110.789.75
                         
1111111609609361222
1.021.031.031.971.981.992.282.763.824.214.654.74.79
-1,382-1,395-1,379-1,167-1,036-956-872-723-53525538262-781
29-43-24-174-306-325-325-305-385-316-390-354-404
-22000011-1-49-1-1-400
-0.35-0.41-0.370.630.640.721.092.293.514.274.84.613.6
134151148128144163192256321385421424361
180157170151135172186175304401385359356
82681109685110127164196335235211266
0000000000000
433525242825727773753153648
0.440.410.450.40.390.470.580.670.891.21.071.531.03
2.642.662.691.861.832.062.652.882.953.174.174.314.86
220112103564132337494164202765
190181216186190175186268339312267247256
3.052.9532.12.062.262.873.233.383.644.644.645.12
3.493.363.462.52.462.733.453.94.274.845.716.176.15
3.142.953.093.133.093.464.536.197.789.1110.5110.789.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Catalent provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Catalent's financial health and stability.

Assets

Catalent's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Catalent must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Catalent after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Catalent's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-23-491521011110983137220585499-256
129152142140140146190228253289378422
-188-15-120-15-135-152649-127
-54-2512-88-101-118-160-121-432-587-288
5755263831778390132-22194538
17220015310782808310298105116188
231421344039234243475399
87137178171155299374247440433439254
-104-122-122-141-139-139-176-218-465-686-660-576
-494-122-171-271-137-309-919-1,510-827-649-1,884-955
-3900-48-1301-169-742-1,292-36137-1,224-379
000000000000
0.35-0.04-0.04-0.73-0.020.170.420.150.050.11.020.49
0000.95000.281.091.050.120.030
0.35-0.05-0.040.2-0.030.160.671.210.141.030.52
-1-10-7-22-14-11-29-39-56-55-1332
00000000-36-22-40
-66-32-3276-19156121-64607-57-447-169
-16.315.255.930.815.7159.719829.6-25.5-253-221-322
000000000000

Catalent stock margins

The Catalent margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Catalent. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Catalent.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Catalent's sales revenue. A higher gross margin percentage indicates that the Catalent retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Catalent's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Catalent's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Catalent's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Catalent. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Catalent's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Catalent Margin History

Catalent Gross marginCatalent Profit marginCatalent EBIT marginCatalent Profit margin
2030e21.75 %0 %12.86 %
2029e21.75 %0 %11.3 %
2028e21.75 %20.64 %9.71 %
2027e21.75 %13.17 %7.92 %
2026e21.75 %10.47 %5.43 %
2025e21.75 %9.4 %4.29 %
202421.75 %-0.25 %-23.81 %
202324.4 %2.65 %-6.01 %
202233.61 %15.18 %10.06 %
202133.82 %16.16 %13.23 %
202031.78 %13.1 %5.59 %
201931.97 %11.64 %5.46 %
201830.55 %11.77 %3.39 %
201731.54 %12.14 %5.29 %
201631.79 %12.42 %6.03 %
201533.61 %15.18 %11.59 %
201432.75 %14.43 %0.89 %
201331.58 %12.66 %-2.76 %
201232.96 %12.42 %-1.44 %
201132.78 %13.96 %-3.53 %
201029.78 %11.54 %-19.56 %
200927.22 %9.96 %-22.03 %

Catalent Stock Sales Revenue, EBIT, Earnings per Share

The Catalent earnings per share therefore indicates how much revenue Catalent has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Catalent earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Catalent's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Catalent’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Catalent's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Catalent Revenue, EBIT and net profit per share

DateCatalent Sales per ShareCatalent EBIT per shareCatalent Earnings per Share
2030e37.6 undefined0 undefined4.83 undefined
2029e34.66 undefined0 undefined3.92 undefined
2028e32.05 undefined0 undefined3.11 undefined
2027e30.78 undefined0 undefined2.44 undefined
2026e28.35 undefined0 undefined1.54 undefined
2025e26.23 undefined0 undefined1.13 undefined
202424.2 undefined-0.06 undefined-5.76 undefined
202323.55 undefined0.62 undefined-1.41 undefined
202226.98 undefined4.1 undefined2.71 undefined
202123.52 undefined3.8 undefined3.11 undefined
202020.32 undefined2.66 undefined1.14 undefined
201917.25 undefined2.01 undefined0.94 undefined
201818.49 undefined2.18 undefined0.63 undefined
201716.38 undefined1.99 undefined0.87 undefined
201614.68 undefined1.82 undefined0.89 undefined
201515.09 undefined2.29 undefined1.75 undefined
201424.02 undefined3.47 undefined0.21 undefined
201324 undefined3.04 undefined-0.66 undefined
201222.48 undefined2.79 undefined-0.32 undefined
201113.06 undefined1.82 undefined-0.46 undefined
201012.62 undefined1.46 undefined-2.47 undefined
200911.92 undefined1.19 undefined-2.63 undefined

Catalent business model

Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.com.

Catalent SWOT Analysis

Strengths

Catalent Inc has a strong global presence, with operations in various countries, allowing it to tap into diverse markets and customer base.

The company has a wide range of capabilities and expertise in pharmaceutical and biotechnology services, including drug development, clinical manufacturing, packaging, and supply chain management.

Catalent Inc has established strong relationships with key pharmaceutical and biotech companies, resulting in long-term partnerships and repeat business.

Weaknesses

The company may face high dependence on a few major clients, which poses the risk of reduced revenues and profitability if these clients shift their business elsewhere.

Catalent Inc's reliance on a complex supply chain network can lead to potential disruptions and challenges in managing inventory and distribution.

Limited brand recognition compared to some competitors may impact Catalent Inc's ability to attract new customers and gain market share.

Opportunities

Growing demand for pharmaceutical and biotechnology services, driven by the increasing need for personalized medicine and advancements in drug development, presents significant growth opportunities for Catalent Inc.

Expansion into emerging markets, such as Asia and Latin America, where the demand for pharmaceutical and biotech services is increasing, can help Catalent Inc diversify its customer base and revenue streams.

Catalent Inc can leverage its expertise in drug delivery technologies to tap into the growing market for specialty pharmaceuticals and targeted therapies.

Threats

Intense competition within the pharmaceutical and biotech services industry poses a threat to Catalent Inc's market share and pricing power.

Regulatory changes and stringent quality requirements in the pharmaceutical industry can increase compliance costs and pose challenges for Catalent Inc's operations.

Economic downturns or fluctuations in healthcare spending can impact the demand for pharmaceutical and biotech services, potentially affecting Catalent Inc's financial performance.

Catalent Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Catalent Revenue by Segment

Segmente202220212020201920182017201620152014
Manufacturing & Commercial Product Supply2.09 B USD1.87 B USD-1.59 B USD-----
Development Services2.35 B USD1.76 B USD-645.5 M USD-----
Clinical Supply Services400 M USD391 M USD-321.4 M USD-----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Catalent Revenue by Segment

Segmente202220212020201920182017201620152014
Manufacturing & Commercial Product Supply--1.74 B USD------
Development Services--1.02 B USD------
Clinical Supply Services--345 M USD------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Catalent Revenue by Segment

Segmente202220212020201920182017201620152014
Total Catalent before inter-segment revenue elimination4.85 B USD4.02 B USD3.1 B USD2.56 B USD-----
Biologics2.55 B USD1.93 B USD1.02 B USD------
Softgel Technologies---872.1 M USD917.3 M USD855.3 M USD775 M USD--
Softgel and Oral Technologies1.25 B USD1.01 B USD1.06 B USD------
Clinical Supply Services400 M USD391 M USD345 M USD321.4 M USD430.4 M USD348.8 M USD307.5 M USD--
Oral and Specialty Drug Delivery650 M USD686 M USD675.9 M USD------
Drug Delivery Solutions-----910.1 M USD806.4 M USD--
Biologics and Specialty Drug Delivery---742.1 M USD601.9 M USD----
Oral Drug Delivery---619.9 M USD573.9 M USD----
Development and Clinical Services-------438.8 M USD412.2 M USD
Oral Technologies-------391.5 M USD358.2 M USD
Medication Delivery Solutions-------261.9 M USD246.1 M USD

Catalent Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Catalent Revenue by Segment

DateConsolidation, EliminationsEuropeInternational OtherRest of WorldUnited StatesUntied States
2024-1.36 B USD356 M USD-2.82 B USD-
2023-1.26 B USD355 M USD-2.77 B USD-
2022-1.51 B USD327 M USD-3.11 B USD-
2021-1.34 B USD288 M USD-2.46 B USD-
2020-976.1 M USD375.8 M USD--1.82 B USD
2019-842.1 M USD433.8 M USD--1.32 B USD
2018-69.5 M USD897.8 M USD-415.3 M USD1.22 B USD-
2017-63.4 M USD797.4 M USD-345 M USD996.4 M USD-
2016-57.2 M USD733.2 M USD-313.5 M USD858.6 M USD-
2015-32.5 M USD795.4 M USD-268.6 M USD799.3 M USD-
2014-22.2 M USD888.8 M USD-278.8 M USD682.3 M USD-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Catalent Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Catalent historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Catalent shares outstanding

The number of shares was Catalent in 2024 — This indicates how many shares 181 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Catalent earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Catalent's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Catalent’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Catalent's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Catalent.

Catalent latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.06 -0.13  (-335.93 %)2025 Q1
6/30/20240.48 0.65  (36.47 %)2024 Q4
3/31/20240.21 -0.06  (-128.16 %)2024 Q3
12/31/2023-0.02 -0.24  (-1,032.08 %)2024 Q2
9/30/2023-0.14 -0.1  (28.01 %)2024 Q1
6/30/20230.11 0.09  (-14.77 %)2023 Q4
3/31/2023-0.03 -0.09  (-219.15 %)2023 Q3
12/31/20220.7 0.67  (-4.49 %)2023 Q2
9/30/20220.57 0.34  (-40.25 %)2023 Q1
6/30/20221.17 1.19  (1.29 %)2022 Q4
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Catalent stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

58

👫 Social

58

🏛️ Governance

39

Environment

Scope 1 - Direct Emissions
94,500
Scope 2 - Indirect emissions from purchased energy
150,100
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
244,600
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees44
Percentage of women in management
Percentage of Asian employees11.2
Share of Asian management
Percentage of Hispanic/Latino employees7.6
Hispano/Latino Management share
Percentage of Black employees13.4
Black Management Share
Percentage of white employees62.1
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Catalent shareholders

%
Name
Stocks
Change
Date
11.19090 % The Vanguard Group, Inc.20,312,603-16,1686/30/2024
6.05932 % Nomura Securities Co., Ltd.10,998,280-262,9146/30/2024
5.28471 % BlackRock Institutional Trust Company, N.A.9,592,27870,7426/30/2024
4.04277 % State Street Global Advisors (US)7,338,040-83,2246/30/2024
2.70603 % Capital World Investors4,911,723-4,744,8376/30/2024
2.56494 % T. Rowe Price Associates, Inc.4,655,622-229,7566/30/2024
2.52811 % Norges Bank Investment Management (NBIM)4,588,7762,006,5136/30/2024
2.40976 % Balyasny Asset Management LP4,373,9513,449,5346/30/2024
2.37489 % Geode Capital Management, L.L.C.4,310,664136,4676/30/2024
2.29542 % Capital Research Global Investors4,166,410-410,9719/30/2024
1
2
3
4
5
...
10

Catalent Executives and Management Board

Mr. Alessandro Maselli

(51)
Catalent President, Chief Executive Officer, Director (since 2016)
Compensation 6.58 M

Dr. Aristippos Gennadios

(58)
Catalent Group President - Pharma and Consumer Health
Compensation 3.8 M

Mr. Ricky Hopson

(48)
Catalent President, Division Head for BioProduct Delivery and Chief of Staff
Compensation 972,307

Mr. J. Martin Carroll

(73)
Catalent Independent Director (since 2015)
Compensation 426,355

Mr. John Greisch

(68)
Catalent Executive Chairman of the Board (since 2018)
Compensation 400,861
1
2
3
4
...
5

Catalent Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Arcturus Therapeutics Stock
Arcturus Therapeutics
SupplierCustomer0,930,250,710,900,900,02
Blueprint Medicines Stock
Blueprint Medicines
SupplierCustomer0,920,340,540,860,880,49
Prothena Stock
Prothena
SupplierCustomer0,910,040,680,890,880,80
Phathom Pharmaceuticals Stock
Phathom Pharmaceuticals
SupplierCustomer0,86-0,050,300,580,61-0,08
Moderna Stock
Moderna
SupplierCustomer0,840,500,730,920,860,86
Aurinia Pharmaceuticals Stock
Aurinia Pharmaceuticals
SupplierCustomer0,820,560,750,750,700,58
Sarepta Therapeutics Stock
Sarepta Therapeutics
SupplierCustomer0,800,150,550,690,53-0,56
Simulations Plus Stock
Simulations Plus
SupplierCustomer0,800,060,250,440,08-0,34
BeiGene Stock
BeiGene
SupplierCustomer0,78-0,080,360,770,780,64
Passage Bio Stock
Passage Bio
SupplierCustomer0,710,270,680,830,62-0,22
1
2
3
4

Most common questions regarding Catalent

What values and corporate philosophy does Catalent represent?

Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.

In which countries and regions is Catalent primarily present?

Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.

What significant milestones has the company Catalent achieved?

Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.

What is the history and background of the company Catalent?

Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.

Who are the main competitors of Catalent in the market?

The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.

In which industries is Catalent primarily active?

Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Catalent?

Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.

What is the P/E ratio of Catalent 2025?

The Catalent P/E ratio is 56.2.

What is the P/S ratio of Catalent 2025?

The Catalent P/S ratio is 2.41.

What is the Quality Investing of Catalent?

The Quality Investing for Catalent is 3/10.

What is the revenue of Catalent 2025?

The expected Catalent revenue is 4.76 B USD.

How high is the profit of Catalent 2025?

The expected Catalent profit is 204.45 M USD.

What is the business model of Catalent

Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.

What is the Catalent dividend?

Catalent pays a dividend of 0 USD distributed over payouts per year.

How often does Catalent pay dividends?

The dividend cannot currently be calculated for Catalent or the company does not pay out a dividend.

What is the Catalent ISIN?

The ISIN of Catalent is US1488061029.

What is the Catalent WKN?

The WKN of Catalent is A112H2.

What is the Catalent ticker?

The ticker of Catalent is CTLT.

How much dividend does Catalent pay?

Over the past 12 months, Catalent paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Catalent is expected to pay a dividend of 0 USD.

What is the dividend yield of Catalent?

The current dividend yield of Catalent is .

When does Catalent pay dividends?

Catalent pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Catalent?

Catalent paid dividends every year for the past 0 years.

What is the dividend of Catalent?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Catalent located?

Catalent is assigned to the 'Health' sector.

Wann musste ich die Aktien von Catalent kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Catalent from 1/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/20/2025.

When did Catalent pay the last dividend?

The last dividend was paid out on 1/20/2025.

What was the dividend of Catalent in the year 2024?

In the year 2024, Catalent distributed 0 USD as dividends.

In which currency does Catalent pay out the dividend?

The dividends of Catalent are distributed in USD.

All fundamentals about Catalent

Our stock analysis for Catalent Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalent Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.